Fosaprepitant
This injectable prodrug is rapidly converted to aprepitant in the body to block substance P signaling in the brain, preventing the nausea and vomiting caused by chemotherapy. It is given intravenously before chemotherapy as part of a combination antiemetic regimen.
आणविक भार
614.4000 g/mol
LogP
1.00
TPSA
124.00 Ų
लिपिंस्की RO5
अनुत्तीर्ण
चिकित्सीय क्षेत्र
क्रिया का तंत्र
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
2D संरचना
Cite this structure
Embed this structure
SMILES
C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
InChI
InChI=1S/C23H22F7N4O6P/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)40-20-19(13-2-4-17(24)5-3-13)33(6-7-39-20)11-18-31-21(35)34(32-18)41(36,37)38/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H,31,32,35)(H2,36,37,38)/t12-,19+,20-/m1/s1
Molecular Formula
C23H22F7N4O6P
HBD / HBA
3 / 15
घूर्णनीय बंधन
7
भारी परमाणु
41
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
अक्सर पूछे जाने वाले प्रश्न
This injectable prodrug is rapidly converted to aprepitant in the body to block substance P signaling in the brain, preventing the nausea and vomiting caused by chemotherapy. It is given intravenously before chemotherapy as part of a combination antiemetic regimen.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Fosaprepitant is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1199324. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 135413538. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="fosaprepitant"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/fosaprepitant/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/fosaprepitant/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/fosaprepitant/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="fosaprepitant"></drugfyi-drug>